Cyclophosphamide + abatacept + Methotrexate + Tacrolimus

Phase 2Completed

0 watching 0 views this week⚡ Active

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

GVHD

Conditions

GVHD, Hematologic Neoplasms

Trial Timeline

Nov 26, 2019 → Jun 15, 2023

NCT ID

NCT03680092

About Cyclophosphamide + abatacept + Methotrexate + Tacrolimus

Cyclophosphamide + abatacept + Methotrexate + Tacrolimus is a phase 2 stage product being developed by Bristol Myers Squibb for GVHD. The current trial status is completed. This product is registered under clinical trial identifier NCT03680092. Target conditions include GVHD, Hematologic Neoplasms.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03680092	Phase 2	Completed	Nov 26, 2019	Jun 15, 2023	GVHD

Competing Products

19 competing products in GVHD

See all competitors

Product	Company	Stage	Hype Score
Prednisone + Jakavi(ruxolitinib) + Prednisone	Novartis	Phase 2	52
Rituximab	Roche	Phase 2	52
Efavaleukin Alfa	Amgen	Phase 1/2	40
AMG 592	Amgen	Phase 1	32
AMG 592	Amgen	Phase 1	32
milatuzumab	Gilead Sciences	Phase 1	32
Itacitinib + Prednisone + Methylprednisolone	Innovent Biologics	Phase 1/2	40
ALD518 + ALD518 + ALD518	CSL	Phase 1/2	40
Alpha-1 antitrypsin (AAT) + Placebo	CSL	Phase 3	76
Tacrolimus (Tac) + Methotrexate (MTX) + Ruxolitinib (Rux) + Cyclophosphamide + Mycophenolate mofetil (MMF)	Incyte	Phase 3	74
Ruxolitinib	Incyte	Pre-clinical	20
Itacitinib + Placebo + Prednisone + Methylprednisolone	Incyte	Phase 3	74
Ruxolitinib + Prednisone	Incyte	Phase 2	49
Itacitinib (200 mg) + Itacitinib (300 mg) + prednisone or methylprednisolone (corticosteroids)	Incyte	Phase 1	30
Ruxolitinib + Extracorporeal photopheresis (ECP) + Low-dose methotrexate (MTX) + Mycophenolate mofetil (MMF) + mechanistic Target of Rapamycin (mTOR) inhibitors (everolimus or sirolimus) + Infliximab + Rituximab + Pentostatin + Imatinib + Ibrutinib	Incyte	Phase 3	74
Ruxolitinib + Prednisone or methylprednisolone	Incyte	Phase 2	49
Ruxolitinib	Incyte	Pre-clinical	20
Itacitinib + Tocilizumab	Incyte	Phase 1	30
remestemcel-L	Mesoblast	Phase 3	72

Other Products from Bristol Myers Squibb

DeucravacitinibApproved

Aripiprazole + Olanzapine + HaloperidolApproved

Irbesartan + CiprofibrateApproved

Entecavir + Lamivudine Placebo + Lamivudine + Entecavir PlaceboApproved

deucravacitinibApproved